34results about How to "Improve drug quality" patented technology

The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

The invention discloses an anti-tumor traditional Chinese medicine. 60-80 parts of sculellaria barbata, 70-90 parts of radix bupleuri, 70-90 parts of cordyceps sinensis, 50-70 parts of American ginseng, 40-60 parts of cyrtomium rhizomes, 30-60 parts of pericarpium citri reticulatae viride and 40-60 parts of isatis roots are added in the formula of the anti-tumor traditional Chinese medicine, a proper number of auxiliary materials are added, 1,000 tablets are prepared, coating is carried out, and the anti-tumor traditional Chinese medicine is prepared. A preparation process of the anti-tumor traditional Chinese medicine is improved. On the premise of guaranteeing that the medicine treatment effect is basically stable, stability of the anti-tumor traditional Chinese medicine in the production process, the medicine quality and the medicine effect are improved, the useful life of the anti-tumor traditional Chinese medicine is prolonged, all ingredient content is still larger than 99.6% after the anti-tumor traditional Chinese medicine is placed for 36 month at room temperature, and the production process of the anti-tumor traditional Chinese medicine achieves substantive breakthrough and technical progress.

The invention discloses a traditional Chinese medicine composition formed by ginkgo biloba extract. The traditional Chinese medicine composition is prepared from, by mass, 24-40% of gingko total flavone, 6-16% of bilobalide, and ginkgolic acid with the amount smaller than 5 ppm. Preferably, the traditional Chinese medicine composition is further prepared from 1-1.68% of quercetin-3-O-glucoside and 2.11-3.53% of quercetin-3-O-2'',6''-dirhamnose glucoside. Preferably, the traditional Chinese medicine composition is further prepared from 1.4-3% of bilobalide A, 0.9-1.8% of bilobalide B and 1.2-1.3% of bilobalide C. Quercetin-3-O-glucoside and quercetin-3-O-2'',6''-dirhamnose glucoside having an important influence on the medicine are definite, the content of quercetin-3-O-glucoside and the content of quercetin-3-O-2'',6''-dirhamnose glucoside are accurately defined as 1-1.68% and 2.11-3.53%, furthermore, biobalide A is clearly defined as 1.4-3%, biobalide B is clearly defined as 0.9-1.8% and biobalide B is clearly defined as 1.2-1.3%. By making the content of the effective components in the ginkgo biloba extract to be accurate and further affirming the effective components, efficacy of the ginkgo biloba extract is improved.

The present invention discloses one kind of hypertension treating compound preparation and its preparation process. The compound preparation includes one tablet core containing diuretic in effective treating amount and pharmaceutically acceptable carrier, and one coating containing telmisartan in effective treating amount and pharmaceutically acceptable carrier. The content of diuretic is 1.5-10 wt% of the tablet core, and that of telmisartan is 3.5-25 wt% of the coating. The compound preparation is prepared through preparing the tablet core pellet and the coating pellet separately with medicine material and supplementary material and the subsequent pressing the coated tablet in a rotary coating machine. The hypertension treating compound preparation has reliable and safe blood pressure reducing effect and high stability.

A quaility control method for the antiviral oral liquid features that on the basis of existing quality control standards, the gas-phase chromatography method is additionally used to measure the content for patchoulic alcohol to ensure that it is not less than 10 micrograms per 10 ml.

The invention relates to a preparation method and applications of dehydro-lincomycin-free lincomycin hydrochloride, which belong to the field of medical technologies. The preparation method disclosed by the invention comprises the following steps: dissolving dehydro-lincomycin-containing lincomycin hydrochloride serving as a raw material into water or an aqueous alcohol solution; adding palladium on carbon accounting for 1/10-1/200 of the amount of the raw material, and simultaneously stirring and introducing hydrogen into the obtained mixture to react for 1-48 hours, so that dehydro-lincomycin is all reacted to generate lincomycin; and crystallizing lincomycin. According to the preparation method, dehydro-lincomycin in lincomycin hydrochloride has a chemical reaction to generate lincomycin hydrochloride, so that dehydro-lincomycin in the raw material is completely removed; and the raw material can be used for preparing a dehydro-lincomycin-free lincomycin hydrochloride preparation, reducing the impurities in pharmaceutical products, and improving the quality of pharmaceutical products.

The invention relates to a capsule real-time inspection method with double detection, which comprises the following steps: 1) providing a capsule real-time test platform with double detection, which includes a near-infrared detection mechanism, a visible light detection mechanism and a main controller, wherein the near-infrared detection mechanism and the visible light detection mechanism respectively perform defect detection to every capsule and the main controller is respectively connected to the near-infrared detection mechanism and the visible light detection mechanism for determining a capsule rejection strategy according to a defect detection result from the near-infrared detection mechanism and the visible light detection mechanism; and 2) performing inspection with the test platform. According to the method, there are two detection methods are available to detect the capsules, thereby improving reliability of capsule test.

The invention relates to a separation and/or detection method of impurities in atorvastatin calcium. The impurities are atorvastatin calcium enantiomers and/or atorvastatin calcium lactone (impurity H). The method uses high-performance liquid chromatography for separation or detection. A mobile phase of the high-performance liquid chromatography is monohydric alcohol-organic acid-organic base of n-hexane-C1-C6. A volume ratio of the monohydric alcohol-organic acid-organic base of the n-hexane-C1-C6 is 85-98:2-15:0.05-0.5:0.05-0.5. The method can realize effective separation on the three partsof the atorvastatin calcium, the atorvastatin calcium enantiomers and the atorvastatin calcium lactone; and at the same time, the method of the invention can be used for detection of the atorvastatincalcium enantiomers and the atorvastatin calcium lactone, and can effectively improve medicine quality and safety of the atorvastatin calcium.

The invention relates to the technical field of medicine purification, and discloses a highly-pure tacrolimus compound and a preparation method thereof. The method comprises the following steps: preprocessed crude tacrolimus undergoes silver-containing polymer resin column chromatography elution, the above obtained eluate is concentrated, and the above obtained concentrate is re-crystallized to obtain highly-pure tacrolimus. The method has the advantages of simplicity in large-scale production operation, small use amount of a solvent, short production period, low cost and environmental protection; and an HPLC detection result shows that ascomycin and dihydrotacrolimus which are most difficult to separate in the crude tacrolimus are completely removed. The normalization purity of tacrolimus is 99% or above, and obtained tacrolimus crystals have the characteristics of uniform particle size distribution, small internal stress and bulk density, and good stability, fluidity, dispersibility and dissolvability. The quality and the medication safety of tacrolimus are improved.

The invention relates to a drug combination for curing the inflammation of vagina, which adopts the form of a foaming agent, in particular to a foaming agent with the principle agents being metronidazole, clotrimazole and chlorhexidine acetate. The drug combination has the advantages of even distribution, wide coating area and better effect in the vagina by adopting the form, and meanwhile, the drug combination feels more comfortable and has stronger retention property than other forms. In the formula of the foaming agent, the drug combination can permeate into the mucosal folds of the vagina rapidly and effectively by dispersing atomizing particles with the particle diameter being a few micrometers in a foaming manner under the action of pressure; the drug combination has higher absorption rate than the spraying agent with water being the only solvent with the assistance from various fat-soluble auxiliary materials; the drug contamination and the cross contamination are avoided during the administration; the invention has the advantages that the curative effect is fully produced, the administration is sanitary, convenient, safe and reliable without causing the foreign body sensation, and the drug combination is easily accepted by patients; and the invention further has the advantages of drug stability, form stability and long effective duration.

The invention provides a separated compound which is a para-defovir mesylate related substance. The invention also provides an application of the compound, wherein the compound is used for preparing the para-defovir mesylate or a composition containing the para-defovir mesylate.

The invention discloses a Non-turning making method of medium-high temperature Daqu. In a heat preservation yeast room, the pressed yeast blocks are stacked on a frame or a shelf and are uniformly placed in the yeast room, and a fan and an air pipe are introduced; in the fermentation process of Daqu, according to the temperature change of the yeast center, the yeast heating is sequentially divided into six stages, namely a constant room entering stage, a low-temperature heating stage, a medium-temperature heating stage, a high-temperature constant stage, a medium-high-temperature cooling stage and a low-temperature constant stage; wherein the temperature control of each stage is realized by adjusting the frequency of a fresh air valve, the frequency of a fan and an external heat source. Environmental parameters of all positions of the yeast room are adjusted in an air circulation mode, it is guaranteed that environments where yeast blocks are located basically have no difference, and normal fermentation of yeast in the yeast room is achieved.

The present invention discloses a preparation technology of captopril tablets. The tablets are prepared from the following components in weight percentages: captopril, a filler, a disintegrant, a lubricant and an adhesive. Weighing, screening and mixing are conducted, compressable auxiliary materials are used and direct tableting is conducted to prepare the captopril tablets. The preparation technology reduces the content of hydrolyzed impurity captopril disulfide in the captopril, improves the dissolution rate, and is simple, cost-saving, good in stability, etc.

A lyophilized powder of latamoxef sodium for injection and a lyophilization method thereof are provided. The lyophilized powder of latamoxef sodium for injection includes the following raw materials by weight: 20˜40 parts of latamoxef sodium, 8˜15 parts of lyophilized adjuvant, 6˜18 parts of excipient and 30˜55 parts of water; by optimizing a raw material process thereof, the present disclosure prepares lyophilized adjuvant and performs twice drying, so that the raw material has stable quality, less impurities, high purity, less adverse reactions and high efficacy; at the same time, the preparation process is innovated and improved to reduce a preparation temperature and ensure stable quality of a drug solution.